Медицинская литература. Новинки

 

 

 

 

 

 

СОВРЕМЕННАЯ ПАРАДИГМА ПОСЛЕОПЕРАЦИОННОГО ВЕДЕНИЯ БОЛЬНЫХ C ДИФФЕРЕНЦИРОВАННЫМ РАКОМ ЩИТОВИДНОЙ ЖЕЛЕЗЫ

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Румянцев П.О., Ильин А.А., Румянцева У.В., Саенко В.А. Рак
щитовидной железы // М.: ГЭОТАРМедиа, 2009. С. 29–30.
2. Статистика злокачественных новообразований в России и
странах СНГ в 2004 г.// Вестник РОНЦ им. Н.Н. Блохина
РАМН, 2006. Т. 17. №3. С. 47.
3. Дедов И.И., Мельниченко Г.А., Трошина Е.А. и др Спорные
вопросы тактики лечения дифференцированного рака щитовидной железы // Пробл. эндокринол., 2008. Т.54. №2.
С. 14–22.
4. Национальные клинические рекомендации по диагностике и
лечению дифференцированного рака щитовидной железы //
Эндокринная хирургия. 2008. №1(2). С. 3–5.
5. Гарбузов П.И., Дроздовский Б.Я., Родичев А.А. и др. Радиойодтерапия рака щитовидной железы// Практическая онкология, 2007. Т8. №1. С. 42–45.
6. Pacini F., Schlumberger M., Dralle H. et al. The European thyroid
cancer taskforce. European consensus for the management of
patients with differentiated thyroid carcinoma of the follicular
epithelium // Europ. J. Endocrinol., 2006. V. 154. P. 787–803.
7. Davies L, Welch HG. Increasing incidence of thyroid cancer in the
United States, 1973–2002 // JAMA. 2006. V. 295(18).
P. 2179–2182.
8. Barczynski M., Barczynski M.L. Current management of thyroid
cancer – a change of therapeutic strategy over the last 20 years //
Przegl. Lek. 2000. V. 57(5). P. 105–107.
9. Schlumberger M.J., Torlantano M. Papillary and follicular thyroid
carcinoma // Baillieres Best Pract. Res. Clin. Endocrinol. Metab.
2000. V. 14(4). P. 601–613.
10. Salvatori M., Rufini V., Garganese M.C. et al. Radioiodine therapy
in differentiated thyroid carcinoma // Rays. 2000. V. 25(2).
P. 221–238.
11. Tuttle R.M., Ball D.W., Byrd D. et al. Thyroid Carcinoma // J.
Natl. Compr. Canc. Netw. 2010. V. 8. P. 1228–1274.
12. Mazzaferri E.L., Jhiang S.M. Longterm impact of initial surgical
and medical therapy on papillary and follicular thyroid cancer //
Am. J. Med. 1994. V. 97. Р. 418–428.
13. DeGroot L.J., Kaplan E.L., McCormick M. Natural history, treatment, and course of papillary thyroid carcinoma // J. Clin.
Endocrinol. Metab. 1992. V. 71(2). P. 414–424.
14. Samaan N.A., Schultz P.N., Hickey R.C. et al. The results of various
modalities of treatment of well differentiated thyroid carcinomas: a
retrospective review of 1599 patients // J. Clin. Endocrinol. Metab.
1992. V. 75(3). Р. 714–720.
15. Mazzaferri E.L., Jhiang S.M. Differentiated thyroid cancer longterm impact of initial therapy // Trans. Am. Clin. Climatol. Assoc.
1995. V. 106. P. 151–168
16. Taylor T., Specker B., Robbins J. et al. Outcome after treatment of
highrisk papillary and nonHьrthlecell follicular thyroid carcinoma // Ann. Intern. Med. 1998. V. 15(129). Р. 622–627.
17. Sawka A.M., Brierley J.D., Tsang R.W. et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in welldifferentiated thyroid cancer // Endocrinol. Metab. Clin. North. Am. 2008. V. 37(2).
P. 457–480.
18. Hundahl S.A., Fleming I.D., Fremgen A.M. et al. A National Cancer
Data Base report on 53,856 cases of thyroid carcinoma treated in
the U.S., 1985–1995 // Cancer. 1998. V. 15. N. 83(12).
P. 2638–2648.
19. Sanders L.E., Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment // Arch. Surg. 1998.
V. 133(4). P. 419–425.
20. Kim S., Wei J.P., Braveman J.M., Brams D.M. Predicting outcome
and directing therapy for papillary thyroid carcinoma // Arch.
Surg. 2004. V. 139(4). P. 393–394.
21. Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer // Br. J. Surg. 2007. V. 94(5). P. 571–577.
22. Hay I.D., Thompson G.B., Grant C.S. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades
(1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients // World. J. Surg.
2002. V. 26(8). P. 879–885.
23. DeGroot L.J., Kaplan E.L., McCormick M., Straus F.H. Natural
history, treatment, and course of papillary thyroid carcinoma // J.
Clin. Endocrinol. Metab. 1990. V. 71(2). P. 414–424.
24. Mazzaferri E.L. Thyroid remnant 131I ablation for papillary and
follicular thyroid carcinoma // Thyroid. 1997. V. 7(2). P. 265–271.
25. Jung T.S., Kim T.Y., Kim K.W. et al. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid
carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma // Endocr. J. 2007. V. 54(2).
P. 265–274.
26. Cooper D.S., Doherty G.M., Haugen B.R. et al. Revised American
Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer // Thyroid. 2009.
V. 19(11). P. 1167–1214.
27. Hay I.D., Hutchinson M.E., GonzalezLosada T. et al. Papillary
thyroid microcarcinoma: a study of 900 cases observed in a 60-year
period // Surgery. 2008. V. 144(6). P. 980–987.
28. Ross D.S., Litofsky D., Cooper D.S. et al. Recurrence after treatment of micropapillary thyroid cancer // Thyroid. 2009. V. 19(10).
P. 1043–1048.
29. Rosario P.W., Reis J.S., Barroso A.L. et al. Efficacy of low and high
131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on postoperative cervical uptake //
Nucl. Med. Commun. 2004. V. 25(11). P. 1077–1081.
30. Johansen K., Woodhouse N.J., Odugbesan O. Comparison of 1073
MBq and 3700 MBq iodine131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer // J.
Nucl. Med. 1991. V. 32(2). P. 252–254.
31. Doi S.A., Woodhouse N.J, Thalib L. et al. Ablation of the thyroid
remnant and I131 dose in differentiated thyroid cancer: a meta-analysis revisited // Clin. Med. Res. 2007. V. 5(2). P. 87–90.
32. Hackshaw A., Harmer C., Mallick U. et al. 131I activity for remnant
ablation in patients with differentiated thyroid cancer: a systematic review // J. Clin. Endocrinol. Metab. 2007. V. 92(1). P. 28–38.
33. Maenpaa H.O., Heikkonen J., Vaalavirta L. et al. Low vs. high
radioiodine activity to ablate the thyroid after thyroidectomy for
cancer: a randomized study // PLoS One. 2008. V. 3(4). P. 1885.
34. Pacini F., Schlumberger M., Harmer C. et al. Post-surgical use of
radioiodine (131I) in patients with papillary and follicular thyroid
cancer and the issue of remnant ablation: a consensus report //
Eur. J. Endocrinol. 2005. V. 153(5). P. 651–659.
35. alNahhas A.M. Ablation in differentiated thyroid carcinoma: Haw
much surgery? How much iodine? // Nucl. Med. Commun. 1999.
V. 20(7). P. 595–597.
36. Menzel C., Grunwald F., Schomburg A. et al. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma // J.
Nucl. Med. 1996. V. 37(9). P. 1496–1503.
37. De Keizer B., Koppeschaar H.P., Zelissen P.M. et al. Efficacy of high
therapeutic doses of iodine131 in patients with differentiated thyroid cancer and detectable serum thyroglobulin // Eur. J. Nucl.
Med. 2001. V. 28(2). P.198–202.
38. Verkooijen R.B., Stokkel M.P., Smit J.W. Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptakerelated ablation strategy // Eur. J. Nucl. Med. Mol. Imaging. 2004.
V. 31(4). P. 499–506.
39. Luster M., Lippi F., Pacini F. et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review // Endocr. Relat. Cancer. 2005. V. 12(1). P. 49–64.
40. Mazzaferri E.L., Kloos R.T. Using recombinant human TSH in the
management of welldifferentiated thyroid cancer: current strategies and future directions // Thyroid. 2000. V. 10(9). P. 767–778.
41. Elisei R., Schlumberger M., Driedger A. et al. Follow-up of low-risk
differentiated thyroid cancer patients who underwent radioiodine
ablation of postsurgical thyroid remnants after either recombinant
human thyrotropin or thyroid hormone withdrawal // J. Clin.
Endocrinol. Metab. 2009. V. 94(11). P. 4171–4179.
42. Bombardieri E., Seregni E., Villano C. et al. Recombinant human
thyrotropin (rhTSH) in the followup and treatment of patients
with thyroid cancer // Tumori. 2003. V. 89(5). P. 533–536.
43. Emerson C.H., Torres M.S. Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential
use // BioDrugs. 2003. V. 17(1). P. 19–38.
44. Hilts S.V., Hellman D., Anderson J. et al. Serial TSH determinations after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinomas // J. Nucl. Med. 1979. V. 20. P. 928–932.
45. Mazzaferri E.L. Radioiodine and other treatments and outcomes.
In: Braverman L.E., Utiger R.D., Ingbar S.H., Werner S.C.
Werner and Ingbar’s the thyroid: a fundamental and clinical textbook // 8th ed. Philadelphia: LippincottWilliams, Wilkins. 2000.
P. 904–929.
46. Meier C.A., Braverman L.E., Ebner S. et al. Diagnostic use of
recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study) // J. Clin. Endocrinol. Metab. 1994. V. 78.
P. 188–196.
47. Tamai H., Suemastu H., Kurokawa N. et al. Alterations in circulating thyroid hormones and thyrotropin after complete thyroidectomy // J. Clin. Endocrinol. Metab. 1979. V. 48. P. 54–58.
48. Klain M.R.M., Leboulleux S., Baudin E., Schlumberger M.
Radioiodine therapy for papillary and follicular thyroid carcinoma // Eur. J. Nucl. Med. Mol. Imaging. 2002; 29 (suppl 2):
S. 479–S85.
49. Singer P.A., Cooper D.S., Daniels G.H. et al. Treatment guidelines
for patients with thyroid nodules and welldifferentiated thyroid
cancer // Arch. Intern. Med. 1996. V. 156. P. 2165–2172.
50. Meier D.A., Brill D.R., Becker D.V. et al. Procedure guideline for
therapy of thyroid disease with 131 iodine // J. Med. Nucl. 2002.
V. 43. P.856–861.
51. Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients // Clin. Endocrinol. (Oxf). 2002.
V. 57. P. 523–527.
52. Serhal D.I., Nasrallah M.P., Arafah B.M. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine
administration to patients with differentiated thyroid cancer //
J. Clin. Endocrinol. Metab. 2004. V. 89(7). P. 3285–3289.
53. Sanchez R., EspinozadelosMonteros A.L., Mendoza V. Adequate
thyroidstimulating hormone levels after levothyroxine discontinuation in the followup of patients with welldifferentiated thyroid
carcinoma // Arch. Med. Res. 2002. V. 33. P. 478–481.
54. Grigsby P.W., Siegel B.A., Bekker S. et al. Preparation of patients
with thyroid cancer for 131I scintigraphy or therapy by 1–3 weeks
of thyroxine discontinuation // J. Nucl. Med. 2004. V. 45(4).
P. 567–570.
55. Leboeuf R., Perron P., Carpentier A.C. et al. LT3 preparation for
wholebody scintigraphy: a randomizedcontrolled trial // Clinical
Endocrinology. 2007. V. 67(6). P. 839–844.
56. Lee J., Yun M.J., Nam K.H. et al. Quality of life and effectiveness
comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroidstimulating hormone administration
for lowdose radioiodine remnant ablation of differentiated thyroid
carcinoma // Thyroid. 2010. V. 20(2). P. 173–179.
57. Taпeb D., Sebag F., Cherenko M. et al. Quality of life changes and
clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH
(rhTSH): a randomized controlled study // Clin. Endocrinol.
(Oxf). 2009. V. 71(1). P. 115–123.
58. Solans R., Bosch J.A., Galofre P. et al. Salivary and lacrimal gland
dysfunction (sicca syndrome) after radioiodine therapy // J. Nucl
Med. 2001. V. 42(5). P. 738–743.
59. Sherman S.I., Brierley J.D., Sperling M. et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of
staging and outcome. National Thyroid Cancer Treatment
Cooperative Study Registry Group // Cancer. 1998. V. 83.
P. 1012–1021.
60. Brierley J.D., Panzarella T., Tsang R.W. et al. A comparison of different staging systems predictability of patient outcome. Thyroid
carcinoma as an example // Cancer. 1997. V 79. P. 2414–2423.
61. Loh K.C., Greenspan F.S., Gee L. et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients // J. Clin.
Endocrinol. Metab. 1997. V. 82. P. 3553–3562.
62. Wittekind C., Compton C.C., Greene F.L. et al. TNM residual
tumor classification revisited // Cancer. 2002. V. 94. P. 2511–2516.
63. Hay I.D., Bergstralh E.J., Goellner J.R. et al. Predicting outcome in
papillary thyroid carcinoma: development of a reliable prognostic
scoring system in a cohort of 1779 patients surgically treated at one
institution during 1940 through 1989 // Surgery. 1993. V. 114.
P. 1050–1057.
64. Byar D.P., Green S.B., Dor P. et al. A prognostic index for thyroid
carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative
Group // Eur. J. Cancer. 1979. V. 15. P. 1033–1041.
65. Shaha A.R., Loree T.R., Shah J.P. Prognostic factors and risk
group analysis in follicular carcinoma of the thyroid // Surgery.
1995. V. 118. P. 1131–1136.
66. Shaha A.R. Controversis in the management of thyroid nodule //
Laryngoscope. 2000. V. 110. P. 183–193.
67. Schlumberger M., Berg G., Cohen O. et al. Follow-up of low-risk
patients with differentiated thyroid carcinoma: a European perspective // Eur. J. Endocrinol. 2004. V. 150. P. 105–112.
68. Rouxel A., Hejblum G., Bernier M.O. et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas // J. Clin. Endocrinol.
Metab. 2004. V. 89. P. 5362–5368.
69. Wenig B.M., Thompson L.D., Adair C.F. et al. Thyroid papillary
carcinoma of columnar cell type: a clinicopathologic study of 16
cases // Cancer. 1998. V. 82. P. 740–753.
70. Akslen L.A., Livolsi V.A. Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma // Cancer. 2000. V. 88. P. 1902–1908.
71. Tuttle R.M., Leboeuf R. Follow up approaches in thyroid cancer: a
risk adapted paradigm // Endocrinol. Metab. Clin. North. Am.
2008. V. 37. P. 419–435.
72. Esnajla N.F., Cantor S.B., Sherman S.I. et al. Optimal treatment
strategy in patients with papillary thyroid cancer: A decision analysis // J. Surgery. 2001. V. 130. P. 921–930.
73. Cooper D.S., Specker B., Ho M. et.al. Thyrotropin suppression and
disease progression in patients with differentiated thyroid cancer:
results from the National Thyroid Cancer Treatment Cooperative
Registry // Thyroid. 1998. V. 8. P. 737–744.
74. Vera P., KuhnLansoy C., EdetSanson A. et al. Does recombinant
human thyrotropinstimulated positron emission tomography with
[18F]fluoro2deoxyDglucose improve detection of recurrence
of welldifferentiated thyroid carcinoma in patients with low serum
thyroglobulin? // Thyroid. 2010. V. 20(1). P. 15–23.
75. Haugen B.R., Pacini F., Reiners C. et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the
detection of thyroid remnant or cancer // J. Clin. Endocrinol.
Metab. 1999. V. 84. P. 3877–3885.
76. Robbins R.J., Tuttle R.M., Sharaf R.N. et al. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are
comparable for the detection of residual differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 2001. V. 86. P. 619–625.
77. Pacini F., Molinaro E., Lippi F. et al. Prediction of disease status by
recombinant human TSHstimulated serum Tg in the postsurgical
followup of differentiated thyroid carcinoma // J. Clin.
Endocrinol. Metab. 2001. V. 86. P. 5686–5690.
78. Haugen B.R., Ridgway E.C., McLaughlin B.A. et al. Clinical comparison of wholebody radioiodine scan and serum thyroglobulin
after stimulation with recombinant human thyrotropin // Thyroid.
2002. V. 12. P. 37–43.
79. Pacini F., Capezzone M., Elisei R. et al. Diagnostic 131iodine
wholebody scan may be avoided in thyroid cancer patients who
have undetectable stimulated serum Tg levels after initial treatment // J. Clin. Endocrinol. Metab. 2002. V. 87. P. 1499–1501.
80. Robbins R.J., Chon J.T., Fleisher M. et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by
itself, to monitor for residual thyroid carcinoma? // J. Clin.
Endocrinol. Metab. 2002. V. 87. P. 3242–3247.
81. Wartofsky L. Management of lowrisk welldifferentiated thyroid
cancer based only on thyroglobulin measurement after recombinant human thyrotropin // Thyroid. 2002. V.12. P. 583–590.
82. Mazzaferri E.L., Robbins R.J., Spencer C.A. et al. A consensus
report of the role of serum thyroglobulin as a monitoring method
for lowrisk patients with papillary thyroid carcinoma // J. Clin.
Endocrinol. Metab. 2003. V. 88. P. 1433–1441.
83. Pacini F., Molinaro E., Castagna M.G. et al. Recombinant human
thyrotropinstimulated serum thyroglobulin combined with neck
ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 2003. V. 8.
P. 3668–3673.
84. Kloos R.T., Mazzaferri E.L. A single recombinant human thyrotropinstimulated serum thyroglobulin measurement predicts
differentiated thyroid carcinoma metastases three to five years
later // J. Clin. Endocrinol. Metab. 2005. V. 90. P. 5047–5057.
85. Mazzaferri E.L., Robbins R.J., Braverman L.E. et al. Author’s
response: a consensus report of the role of serum thyroglobulin as
a monitoring method for lowrisk patients with papillary thyroid
carcinoma // J. Clin. Endocrinol. Metab. 2003. V. 88.
P. 4508–4509.
86. Smallridge R.C., Meek S.E., Morgan M.A. et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to
rhTSHstimulated thyroglobulin in followup of thyroid cancer
patients // J. Clin. Endocrinol. Metab. 2007. V. 92(1). P. 82–87.
87. Ericsson U.B., Christensen S.B., Thorell J.I. A high prevalence of
thyroglobulin autoantibodies in adults with and without thyroid
disease as measured with a sensitive solidphase immunosorbent
radioassay // Clin. Immunol. Immunopathol. 1985. V. 37.
P. 154–162.
88. Kumar A., Shah Dh., Shrihari U. et al. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma //
Thyroid. 1994. V. 4. P. 199–202.
89. Spencer C.A., Takeuchi M., Kazarosyan M. et al. Serum thyroglobulin futoantibodies: prevalence, influence on serum thyroglobulin
measurement, and prognostic significance in patients with differentiated thyroid carcinoma // J. Clin. Endocrinol. Metab. 1998.
V. 83(4). P. 1121–1127.
90. Pacini F., Fugazzola L., Lippi F. et al. Detection of thyroglobulin in
fine needle aspirates of nonthyroidal neck masses: a clue to the
diagnosis of metastatic differentiated thyroid cancer // J. Clin.
Endocrinol. Metab. 1992. V. 74(6). P. 1401–1404.
91. Gharib H., Papini E., Paschke R. et al. AACE/AME/ETA Task
Force on Thyroid Nodules. American Association of Clinical
Endocrinologists, Associazione Medici Endocrinologi and
European Thyroid Association Medical Guidelines for Clinical
Practice for the Diagnosis and Management of Thyroid Nodules //
Endocr. Pract. 2010. V. 16(1). P. 1–43.
92. Boi F., Baghino G., Atzeni F. et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fineneedle aspiration biopsy of
neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies // J. Clin. Endocrinol. Metab. 2006. V. 91(4).
P. 1364–1369.
93. Whitley R.J., Ain K.B. Thyroglobulin: a specific serum marker for
the management of thyroid carcinoma // Clin. Lab. Med. 2004. V.
24.P. 29–47.
94. Milas M., Barbosa G.F., Mitchell J. et al. Effectiveness of peripheral thyrotropin receptor mRNA in followup of differentiated thyroid cancer // Ann. Surg. Oncol. 2009. V. 16(2

Modern paradigm of postoperative management in patients with well-differentiated thyroid cancer

Keywords: